JP2011506591A5 - - Google Patents

Download PDF

Info

Publication number
JP2011506591A5
JP2011506591A5 JP2010538900A JP2010538900A JP2011506591A5 JP 2011506591 A5 JP2011506591 A5 JP 2011506591A5 JP 2010538900 A JP2010538900 A JP 2010538900A JP 2010538900 A JP2010538900 A JP 2010538900A JP 2011506591 A5 JP2011506591 A5 JP 2011506591A5
Authority
JP
Japan
Prior art keywords
independently
piperazino
compound according
alkyl
saturated aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010538900A
Other languages
English (en)
Japanese (ja)
Other versions
JP5511680B2 (ja
JP2011506591A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2008/004208 external-priority patent/WO2009077766A1/en
Publication of JP2011506591A publication Critical patent/JP2011506591A/ja
Publication of JP2011506591A5 publication Critical patent/JP2011506591A5/ja
Application granted granted Critical
Publication of JP5511680B2 publication Critical patent/JP5511680B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010538900A 2007-12-19 2008-12-19 ピリド［２，３−ｂ］ピラジン−８−置換化合物及びその使用 Active JP5511680B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1501907P 2007-12-19 2007-12-19
US61/015,019 2007-12-19
PCT/GB2008/004208 WO2009077766A1 (en) 2007-12-19 2008-12-19 Pyrido[2,3-b]pyrazine-8-substituted compounds and their use

Publications (3)

Publication Number Publication Date
JP2011506591A JP2011506591A (ja) 2011-03-03
JP2011506591A5 true JP2011506591A5 (enrdf_load_stackoverflow) 2012-01-12
JP5511680B2 JP5511680B2 (ja) 2014-06-04

Family

ID=40342728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538900A Active JP5511680B2 (ja) 2007-12-19 2008-12-19 ピリド［２，３−ｂ］ピラジン−８−置換化合物及びその使用

Country Status (18)

Country Link
US (5) US8198279B2 (enrdf_load_stackoverflow)
EP (1) EP2229391B1 (enrdf_load_stackoverflow)
JP (1) JP5511680B2 (enrdf_load_stackoverflow)
KR (1) KR101665143B1 (enrdf_load_stackoverflow)
CN (1) CN101945869B (enrdf_load_stackoverflow)
AU (1) AU2008337286B2 (enrdf_load_stackoverflow)
BR (1) BRPI0821227A2 (enrdf_load_stackoverflow)
CA (1) CA2709257C (enrdf_load_stackoverflow)
DK (1) DK2229391T3 (enrdf_load_stackoverflow)
EA (1) EA019974B1 (enrdf_load_stackoverflow)
ES (1) ES2520940T3 (enrdf_load_stackoverflow)
IL (1) IL206330A (enrdf_load_stackoverflow)
MX (1) MX2010006739A (enrdf_load_stackoverflow)
NZ (1) NZ586418A (enrdf_load_stackoverflow)
PL (1) PL2229391T3 (enrdf_load_stackoverflow)
UA (1) UA105763C2 (enrdf_load_stackoverflow)
WO (1) WO2009077766A1 (enrdf_load_stackoverflow)
ZA (1) ZA201004524B (enrdf_load_stackoverflow)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101945869B (zh) 2007-12-19 2014-06-18 癌症研究技术有限公司 吡啶并[2,3-b]吡嗪-8-取代化合物及其用途
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
EP2531502B1 (en) * 2010-02-01 2014-04-02 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
JP5787977B2 (ja) 2010-04-08 2015-09-30 レスピバート・リミテツド Ｐ３８ｍａｐキナーゼ阻害剤
JP5973426B2 (ja) * 2010-06-17 2016-08-23 レスピバート・リミテツド Ｐ３８ｍａｐｋ阻害剤を含む呼吸器用製剤
WO2011160206A1 (en) 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
KR20140038382A (ko) 2011-03-10 2014-03-28 프로벡투스 파마슈티컬스 인코포레이티드 암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
CN107245056A (zh) 2011-08-26 2017-10-13 润新生物公司 化学实体、组合物及方法
CA2848506C (en) 2011-09-14 2020-07-21 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN103130686B (zh) * 2011-12-02 2016-09-14 天津市国际生物医药联合研究院 N，n′-不对称二芳基取代脲类化合物及其制备方法和用途
WO2013112950A2 (en) 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN108358899B (zh) 2012-04-13 2021-07-27 Epizyme股份有限公司 人类组蛋白甲基转移酶ezh2抑制剂的盐形式
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
NZ746490A (en) 2012-10-02 2018-12-21 Bayer Cropscience Ag Heterocyclic compounds as pesticides
MY180311A (en) 2012-10-15 2020-11-28 Epizyme Inc Substituted benzene compounds
EP2916838B1 (en) 2012-11-12 2019-03-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
ES2960953T3 (es) 2013-10-16 2024-03-07 Epizyme Inc Forma de sal de clorhidrato para la inhibición de EZH2
GB201320729D0 (en) * 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
WO2017144877A1 (en) 2016-02-23 2017-08-31 Cancer Research Technology Limited Dietary product devoid of at least two non essential amino acids
EP3709991A1 (en) 2017-11-13 2020-09-23 Greg Hannon Dietary product
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
GB201818649D0 (en) 2018-11-15 2019-01-02 Univ Sheffield Compounds
GB201818651D0 (en) 2018-11-15 2019-01-02 Univ Sheffield Compounds
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CA3140017A1 (en) 2019-07-19 2021-01-28 Aurore HICK Polyaromatic urea derivatives and their use in the treatment of muscle diseases
PH12022550298A1 (en) 2019-08-08 2023-04-24 B C I Pharma Quinoline derivatives as protein kinase inhibitors
CN115210229A (zh) 2020-01-03 2022-10-18 博格有限责任公司 多环酰胺作为治疗癌症的ube2k调节剂
CA3181158A1 (en) 2020-06-03 2021-12-09 Oliver D. K. MADDOCKS Formulations for personalized methods of treatment
WO2021247923A1 (en) 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer
EP4175957A4 (en) * 2020-06-24 2024-06-26 Purdue Research Foundation 2,3-DISUBSTITUTED PYRIDO[3,4-B!PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS
CN112480109B (zh) * 2020-11-16 2022-04-01 浙江大学 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途
EP4029501A1 (en) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells
CN114105876A (zh) * 2021-12-08 2022-03-01 沈阳科创化学品有限公司 一种制备乙唑螨腈中间体的方法
GB202208347D0 (en) 2022-06-07 2022-07-20 Univ Court Univ Of Glasgow Targets for cancer therapy
GB202209622D0 (en) 2022-06-30 2022-08-17 Institute Of Cancer Res Royal Cancer Hospital Compounds
GB202209624D0 (en) 2022-06-30 2022-08-17 Institute Of Cancer Res Royal Cancer Hospital Prodrugs
CN120239701A (zh) 2022-11-24 2025-07-01 Bci制药公司 作为蛋白激酶抑制剂的吡啶衍生物
CN115884487B (zh) * 2023-02-16 2023-05-26 浙大城市学院 基于针式协同双螺旋电极介质阻挡放电管
TW202448857A (zh) * 2023-05-12 2024-12-16 大陸商正大天晴藥業集團股份有限公司 含有芳香二並環的化合物
WO2025021943A1 (en) 2023-07-26 2025-01-30 Neuralis Quinazolinone, benzoxazinone and benzoxazepinone derivatives as protein kinase inhibitors

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082845A (en) 1977-04-25 1978-04-04 Merck & Co., Inc. 3-(1-Piperazinyl)-pyrido[2,3-b]pyrazines
JPS5665863A (en) 1979-10-31 1981-06-03 Tokyo Organ Chem Ind Ltd Novel aniline derivative, its preparation and pesticide containing the same
JPS5738777A (en) 1980-08-19 1982-03-03 Sogo Yatsukou Kk 2-sufanilamidopyrathyn derivative
US4666828A (en) * 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) * 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) * 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5643755A (en) * 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
JPH10506011A (ja) * 1994-09-22 1998-06-16 ヘルシンキ、ユニバーシティ、ライセンシング、リミテッド、オサケ、ユキチュア レセプターチロシンキナーゼ、ｔｉｅのプロモーター
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5882864A (en) * 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6143764A (en) * 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
ZA971896B (en) * 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
EP0929526B1 (en) 1996-09-25 2005-07-27 AstraZeneca AB Qinoline derivatives inhibiting the effect of growth factors such as vegf
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
KR100547929B1 (ko) 1997-09-26 2006-02-02 젠타리스 게엠베하 세린/트레오닌 단백질 키나제 기능을 조절하기 위한 아자벤즈이미다졸계 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
SK286564B6 (sk) * 1997-12-22 2009-01-07 Bayer Corporation Substituované arylmočoviny ako inhibítory rafkinázy a farmaceutický prípravok s ich obsahom
US20010053946A1 (en) * 1998-09-04 2001-12-20 R. R. Donnelley & Sons Company System for controlling feeders of a package assembly apparatus
WO2000035436A2 (en) 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
BR9916785A (pt) 1999-01-07 2001-10-23 Warner Lambert Co Tratamento de asma com inibidores mek
HU230789B1 (en) * 1999-01-22 2018-05-02 Kyowa Hakko Kirin Co Quinoline derivatives and quinazoline derivatives, pharmaceutical compositions containing them and their use
WO2000045435A1 (en) 1999-01-29 2000-08-03 The University Of Akron Polyimides used as microelectronic coatings
AU5786000A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
RU2002110461A (ru) * 1999-09-21 2004-03-10 Астразенека Аб (Se) Производные хиназолина и их применение в качестве фармацевтических веществ
GB2356398A (en) 1999-11-18 2001-05-23 Lilly Dev Ct S A Preparation of arylsulfamides
AR029423A1 (es) 1999-12-21 2003-06-25 Sugen Inc Compuesto derivado de pirrolo-[pirimidin o piridin]-6-ona, metodo de preparacion de dichos compuestos, composiciones farmaceuticas que los comprenden, un metodo para regular, modular o inhibir la actividad de la proteina quinasa y un metodo de tratar o prevenir una enfermedad de mamiferos
US6492529B1 (en) * 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
EP1341771A2 (en) * 2000-11-29 2003-09-10 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
KR20020096367A (ko) 2001-06-19 2002-12-31 주식회사 티지 바이오텍 관절염 예방 또는 치료제 및 그것의 스크리닝 방법
WO2003056036A2 (en) 2001-12-21 2003-07-10 The Wellcome Trust Genes
US20030180226A1 (en) 2002-01-23 2003-09-25 Haughton Pauline A. Anti-bacterial sneeze spray
EP1534268A4 (en) 2002-08-09 2006-11-02 Merck & Co Inc TYROSINE KINASE INHIBITORS
WO2004083458A1 (en) 2003-03-20 2004-09-30 Universite Catholique De Louvain Medical use of ras antagonists for the treatment of capillary malformation
WO2004110452A1 (en) 2003-06-13 2004-12-23 Novartis Ag 2-aminopyrimidine derivatives as raf kinase inhibitors
CN1917882A (zh) 2004-02-13 2007-02-21 辉瑞产品公司 非典型抗精神病药物与促肾上腺皮质激素释放因子拮抗剂的治疗剂组合
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
EP1789399A1 (en) 2004-08-31 2007-05-30 AstraZeneca AB Quinazolinone derivatives and their use as b-raf inhibitors
US20080207616A1 (en) 2004-10-15 2008-08-28 Astrazeneca Ab Quinoxalines as B Baf Inhhibitors
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
EP1835934A4 (en) 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc ENZYME MODULATORS AND TREATMENTS
WO2007059202A2 (en) 2005-11-15 2007-05-24 Bayer Healthcare Ag Pyrazolyl urea derivatives useful in the treatment of cancer
WO2007064872A2 (en) 2005-12-01 2007-06-07 Bayer Healthcare Llc Urea compounds useful in the treatment of cancer
CN101365682A (zh) 2005-12-08 2009-02-11 千禧药品公司 具有激酶抑制活性的双环化合物
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
CN101040720A (zh) 2006-03-24 2007-09-26 沈华立 一种豆腐干的五香麻辣卤汤液
CN101421253A (zh) * 2006-04-18 2009-04-29 阿斯利康(瑞典)有限公司 喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物
JP2009534457A (ja) 2006-04-26 2009-09-24 キャンサー・リサーチ・テクノロジー・リミテッド がん治療用化合物としてのイミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物およびその類似体
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
WO2008044688A1 (fr) 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Dérivé de l'urée
DK2101819T3 (da) 2006-11-20 2013-04-29 Harvard College Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis
BRPI0814685A2 (pt) 2007-07-10 2019-09-24 Neurin Pharmaceuticals 1991 Ltd variantes com splicing de cd44 em doenças neurodegenerativas
CN101945869B (zh) 2007-12-19 2014-06-18 癌症研究技术有限公司 吡啶并[2,3-b]吡嗪-8-取代化合物及其用途
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
CA2738828A1 (en) 2008-10-02 2010-04-08 Respivert Limited P38 map kinase inhibitors
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
WO2010067130A1 (en) 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
IN2012DN01403A (enrdf_load_stackoverflow) 2009-08-24 2015-06-05 Genentech Inc
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
EP2531502B1 (en) 2010-02-01 2014-04-02 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
JP5787977B2 (ja) 2010-04-08 2015-09-30 レスピバート・リミテツド Ｐ３８ｍａｐキナーゼ阻害剤
US9260410B2 (en) 2010-04-08 2016-02-16 Respivert Ltd. P38 MAP kinase inhibitors
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
JP5973426B2 (ja) 2010-06-17 2016-08-23 レスピバート・リミテツド Ｐ３８ｍａｐｋ阻害剤を含む呼吸器用製剤
GB201010196D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Methods
WO2012008564A1 (ja) 2010-07-16 2012-01-19 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2701694A4 (en) 2011-04-28 2014-10-08 Univ Duke METHOD FOR THE TREATMENT OF HEMOGLOBINOPATHIES
WO2012177725A1 (en) 2011-06-23 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2013001372A2 (en) 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
SG2014005029A (en) 2011-09-01 2014-03-28 Novartis Ag Use of organic compound for the treatment of noonan syndrome
BR112014007694B1 (pt) 2011-10-03 2022-09-27 Respivert Limited Compostos de 1-(3-(tert-butil)-1-(p-tolil)-1h-pirazol-5-il)-3-(4-((2-(fenilamino) pirimidin-4-il)óxi) naftalen-1-il)ureia, seus usos, composição e formulação farmacêutica compreendendo os mesmos
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
WO2014033446A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
US9783556B2 (en) 2012-08-29 2017-10-10 Respivert Limited Kinase inhibitors
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
WO2014140582A1 (en) 2013-03-14 2014-09-18 Respivert Limited Kinase inhibitors
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
DK2981535T3 (da) 2013-04-02 2021-03-01 Oxular Acquisitions Ltd Urinstofderivater, der er anvendelige som kinaseinhibitorer
WO2014162121A1 (en) 2013-04-02 2014-10-09 Topivert Pharma Limited Kinase inhibitors based upon n-alkyl pyrazoles
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2015092423A1 (en) 2013-12-20 2015-06-25 Respivert Limited Urea derivatives useful as kinase inhibitors
AU2015216957B2 (en) 2014-02-14 2019-04-04 Respivert Limited Aromatic heterocyclic compounds as antiinflammatory compounds
EP3201189A1 (en) 2014-10-01 2017-08-09 Respivert Limited N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38

Similar Documents

Publication Publication Date Title
JP2011506591A5 (enrdf_load_stackoverflow)
JP2020506178A5 (enrdf_load_stackoverflow)
JP2018138577A5 (enrdf_load_stackoverflow)
JP2004511462A5 (enrdf_load_stackoverflow)
JP2020505376A5 (enrdf_load_stackoverflow)
JP2019501223A5 (enrdf_load_stackoverflow)
JP2001510843A5 (enrdf_load_stackoverflow)
JP2019500315A5 (enrdf_load_stackoverflow)
WO2010042684A4 (en) Pyrrolotriazine kinase inhibitors
JP2010536887A5 (enrdf_load_stackoverflow)
JP2016506368A5 (enrdf_load_stackoverflow)
JP2005511699A5 (enrdf_load_stackoverflow)
JP2010513519A5 (enrdf_load_stackoverflow)
JP2004534816A5 (enrdf_load_stackoverflow)
JP2017501236A5 (enrdf_load_stackoverflow)
JP2014503525A5 (enrdf_load_stackoverflow)
JP2010524932A5 (enrdf_load_stackoverflow)
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2017504635A5 (enrdf_load_stackoverflow)
JP2020520957A5 (enrdf_load_stackoverflow)
JP2011518819A5 (enrdf_load_stackoverflow)
JP2012513390A5 (enrdf_load_stackoverflow)
JP2018525430A5 (enrdf_load_stackoverflow)
JPH05509307A (ja) プリンの抗ウイルス性ホスホノ―アルケン誘導体
JP2007532582A5 (enrdf_load_stackoverflow)